Who
Stephen C. McCluski
Director
Company insider
Files Form 4 as: Director, Monro; Director, ImmunoGen; Director, Standard Microsystems; Director, Indevus Pharmaceuticals; Senior Vice President, Bausch & Lomb.
In numbers
- Trades disclosed
- 134
- Buys
- 1
- Sells
- 3
- Bought
- $56K
- Sold
- $1.9M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 15 Feb 2006
- Last trade
- 11 Aug 2026
- Last filed
- 12 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Aug 2026filed 12 Aug 2026 | MNRO MonroConsumer Services | SEC FORM 4 Code A | —11,149 at $0.00 | filing |
| 11 Aug 2026filed 12 Aug 2026 | MNRO MonroConsumer Services | SEC FORM 4 Code A | —11,149 at $0.00 | filing |
| 12 Aug 2025filed 13 Aug 2025 | MNRO MonroConsumer Services | SEC FORM 4 Code A | —8,306 at $0.00 | filing |
| 13 Aug 2024filed 15 Aug 2024 | MNRO MonroConsumer Services | SEC FORM 4 Code A | —4,937 at $0.00 | filing |
| 12 Feb 2024filed 12 Feb 2024 | ImmunoGenoption or derivative | SEC FORM 4 Code D | —13,090 | filing |
| 12 Feb 2024filed 12 Feb 2024 | ImmunoGenoption or derivative | SEC FORM 4 Code D | —105,458 | filing |
| 12 Feb 2024filed 12 Feb 2024 | ImmunoGenoption or derivative | SEC FORM 4 Code D | —10,000 | filing |
| 12 Feb 2024filed 12 Feb 2024 | ImmunoGenoption or derivative | SEC FORM 4 Code D | —10,000 | filing |
| 12 Feb 2024filed 12 Feb 2024 | ImmunoGenoption or derivative | SEC FORM 4 Code D | —5,000 | filing |
| 12 Feb 2024filed 12 Feb 2024 | ImmunoGenoption or derivative | SEC FORM 4 Code D | —10,000 | filing |
| 12 Feb 2024filed 12 Feb 2024 | ImmunoGenoption or derivative | SEC FORM 4 Code D | —18,000 | filing |
| 12 Feb 2024filed 12 Feb 2024 | ImmunoGenoption or derivative | SEC FORM 4 Code D | —18,000 | filing |
| 12 Feb 2024filed 12 Feb 2024 | ImmunoGenoption or derivative | SEC FORM 4 Code D | —50,000 | filing |
| 12 Feb 2024filed 12 Feb 2024 | ImmunoGenoption or derivative | SEC FORM 4 Code D | —44,000 | filing |
| 12 Feb 2024filed 12 Feb 2024 | ImmunoGenoption or derivative | SEC FORM 4 Code D | —44,000 | filing |
| 12 Feb 2024filed 12 Feb 2024 | ImmunoGenoption or derivative | SEC FORM 4 Code D | —19,597 | filing |
| 13 Sep 2023filed 14 Sep 2023 | ImmunoGenoption or derivative | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 13 Sep 2023filed 14 Sep 2023 | ImmunoGen | SEC FORM 4 Code M | $147K10,000 at $14.70 | filing |
| 13 Sep 2023filed 14 Sep 2023 | ImmunoGen | SEC FORM 4 Code M | $161K10,000 at $16.05 | filing |
| 15 Aug 2023filed 17 Aug 2023 | MNRO MonroConsumer Services | SEC FORM 4 Code A | —3,749 at $0.00 | filing |
News
Monro Muffler Brake, Inc. (NASDAQ:MNRO) Stock Has Average Price Target of $24.33MNRO · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Stephen C. McCluski; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.